Herwenda (Trastuzumab)

Herwenda is indicated for the treatment of several HER2‑positive malignancies, both in advanced and early disease stages, under physician guidance.

• HER2‑positive metastatic breast cancer, typically in combination with chemotherapy.
• HER2‑positive early‑stage breast cancer as adjuvant therapy after surgery.
• HER2‑positive gastric adenocarcinoma, often with a fluoropyrimidine‑based regimen.
• HER2‑positive gastro‑esophageal junction adenocarcinoma in the metastatic setting.
• HER2‑positive breast cancer with brain metastases when systemic control is needed.

• Trastuzumab binds with high affinity to the extracellular domain IV of the human epidermal growth factor receptor‑2 (HER2) protein on tumor cells. This binding blocks ligand‑independent HER2 signaling, prevents receptor dimerization, and inhibits downstream pathways such as PI3K/AKT and MAPK. Additionally, the Fc region of trastuzumab recruits immune effector cells, leading to antibody‑dependent cellular cytotoxicity that contributes to tumor cell elimination.

Adverse reactions to Herwenda have been observed in clinical practice; they range from mild, frequently reported events to rare but serious conditions.

Common

• Fever, chills, or flu‑like symptoms that may appear during or shortly after the infusion.
• Nausea, vomiting, or loss of appetite, often mild and manageable with supportive care.
• Fatigue or generalized weakness that can persist for several days post‑treatment.

Serious

• Cardiac dysfunction, including a measurable reduction in left ventricular ejection fraction that may require cardiac monitoring.
• Severe allergic reactions (anaphylaxis) presenting with respiratory distress, urticaria, or hypotension.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, requiring immediate medical attention.

Herwenda should be used only after a thorough clinical assessment, and several precautions are recommended to minimize risk.

• Baseline and periodic cardiac evaluation (e.g., echocardiogram) is advised for patients with existing heart disease.
• Infusion should be administered in a setting equipped for emergency management of hypersensitivity reactions.
• Patients with known hypersensitivity to trastuzumab or any component of the formulation should not receive Herwenda.
• Caution is warranted in individuals with impaired hepatic function, as metabolism may be altered.
• Monitor complete blood counts regularly to detect neutropenia or thrombocytopenia.
• Avoid concurrent use with live vaccines due to potential immune modulation.

Herwenda may interact with other agents; awareness of potential pharmacodynamic and pharmacokinetic interactions helps ensure safe co‑administration.

Avoid

• Concurrent use with other HER2‑targeted monoclonal antibodies (e.g., pertuzumab) without specialist guidance, due to overlapping toxicity.
• Live attenuated vaccines during treatment, because immune response may be compromised.
• Concurrent use with other monoclonal antibodies targeting EGFR may increase risk of skin toxicity.

Use with caution

• Anthracycline chemotherapy (e.g., doxorubicin) because of additive cardiac risk.
• Concomitant cardiotoxic agents such as trastuzumab‑deruxtecan or certain tyrosine kinase inhibitors.
• Medications that prolong QT interval, as trastuzumab may rarely affect cardiac repolarization.
• Corticosteroids may mask early signs of infusion reactions; monitor patients closely.